A Phase 1 Study of LY2606368 in Patients With Advanced Cancer.

Trial Profile

A Phase 1 Study of LY2606368 in Patients With Advanced Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Apr 2017

At a glance

  • Drugs Prexasertib (Primary)
  • Indications Anal cancer; Cancer; Head and neck cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 05 Apr 2017 Results (n=71) of a clinical biomarker analysis of prexasertib in patients with advanced head and neck squamous cancer and squamous cell carcinoma of the anus, presented at the 108th Annual Meeting of the American Association for Cancer Research.
    • 19 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 04 Apr 2016 Results published in the Journal of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top